DALLAS and NEW YORK, Jan. 14,
2015 /PRNewswire/ -- PlasmaTech Biopharmaceuticals,
Inc. (NASDAQ: PTBI, PTBIW), a biopharmaceutical company advancing
patient care in critical areas, announced today that Scott Schorer, CEO, will be presenting at
Biotech Showcase™ 2015 Conference being held in San Francisco, CA this week. Details are
as follows:
Event:
|
|
Biotech Showcase™
2015 Conference
|
Date:
|
|
Wednesday, January
14, 2015
|
Time:
|
|
9:30 am Pacific
Time
|
Location:
|
|
D-Powell
(3rd Floor) Parc 55 Wyndham SF Union Square
Hotel
|
Biotech Showcase is an investor and partnering conference
devoted to providing private and public biotechnology and life
sciences companies an opportunity to present to, and meet with,
investors and pharmaceutical executives during the course of one of
the industry's largest annual healthcare investor conferences. Now
in its seventh year, Biotech Showcase is expected to attract
upwards of 1,500 attendees.
About PlasmaTech Biopharmaceuticals, Inc.:
PlasmaTech Biopharmaceuticals, Inc. (PlasmaTech) is a
biopharmaceutical company focused on advancing targeted treatments
for significant unmet needs of critical patient care.
Exploiting two distinct proprietary platforms, Salt Diafiltration
(SDF™) Process and Polymer Hydrogel Technology (PHT™), PlasmaTech
is active in the development and commercialization of
plasma-derived therapeutics and cancer supportive care products.
The company has developed a robust product pipeline that includes
two commercial stage products, MuGard® and ProctiGard™ as well as
multiple pre-clinical follow-on products. For more information
visit, www.plasmatechbio.com.
This press release contains certain statements that are
forward-looking within the meaning of Section 27a of the Securities
Act of 1933, as amended, and that involve risks and uncertainties.
These statements include those relating to: timelines and clinical
results for MuGard and ProctiGard, our ability to achieve clinical
and commercial success and our ability to successfully develop
marketed products. These statements are subject to numerous risks,
including but not limited to PlasmaTech's need to obtain additional
financing in order to continue clinical trials and operations and
to the risks detailed in PlasmaTech's Annual Reports on Form 10-K
and other reports filed by the Company with the Securities and
Exchange Commission.
Company and Media Contact:
Harrison Wehner
President & CFO
PlasmaTech Biopharmaceuticals, Inc.
(617) 981-6955
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/plasmatech-biopharmaceuticals-to-present-at-biotech-showcase-2015-300020484.html
SOURCE PlasmaTech Biopharmaceuticals, Inc.